Quantcast

Industry news that matters to you.  Learn more

Kantar Health Launches CancerMPact Biomarker Analysis

Reading time: 2 minutes

Kantar Health, a leading global healthcare consulting firm, today announced the availability of CancerMPact® Biomarker Analysis, a global offer that examines biomarker segmentation in the current and evolving oncology landscape. The analysis is based on a thorough review of literature and recently published data covering the following biomarkers:

  • BRAF (melanoma)
  • EGFR (non-small lung cancer)
  • EML4-ALK (non-small cell lung cancer)
  • KRAS (colorectal cancer)
  • TNBC (breast cancer)

CancerMPact Biomarker Analysis helps clients identify the percentage of cancer patients with a specific biomarker; ascertain variations in biomarker prevalence by race, ethnicity or geography; determine which information to use to inform forecasting and market sizing; and pinpoint which patient segments are available for targeted therapies and clinical trials. Through this new offer, pharma companies are able to better understand which patient subpopulations are candidates for unique treatment options in this complex therapeutic area.

“The era of ‘personalized’ medicine has arrived, and while physicians and patients are ready to embrace it, many factors need to be considered by a manufacturer to accurately evaluate their market opportunities,” Kantar Health Vice President David Robinson said. “We estimate that 17 to 20 percent of oncology patients are currently eligible for personalized care due to either biomarkers or histology-based treatments. This number will grow in the near future as more biomarkers are validated and new patient subpopulations are identified as being appropriate for novel targeted therapeutics.”

CancerMPact Biomarker Analysis is produced by the same oncology experts as CancerMPact®, which has become an invaluable oncology decision support tool for market analysis, strategic planning and identification of commercial opportunities in the U.S., Western Europe, Japan and China. This tool, composed of web-based integrated modules, includes Treatment Practices and Evolution (Treatment Architecture and Future Trends and Insights), Patient Metrics, and Monthly Drugs and Regimens.